IFNB1 and myeloid sarcoma: Interferon-beta (IFNbeta) is a disease-modifying therapy (DMT) that reduces neuroinflammation in relapsing-remitting (RR) MS, acting on peripheral blood mononuclear cells (PBMCs) with an MRI-detectable effect, confirming the critical role of PBMCs in the CNS damage of disease subjects [4].